chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Patient stopped breathing five days after the vaccine (5/29/21) He was taken to Hospital by paramedics and was put on ventilator in Intensive Care. They took him off the ventilator and he died 6 days after (5/5/21).
Information has been received from a physician concerning a female patient over the age of 65 who on 18-Oct-2005, was vaccinated in the right arm with a 0.5 ml second dose of pneumococcal 23v polysaccharide vaccine (lot 650302/1039P). Subsequently, the patient presented to the office with complaints of "cellulitis type reaction", local pain, swelling, redness and fever. Onset of symptoms was 2 to 3 days post vaccination. The physician reported that the patient was "the anxious type" and was very concerned about the reaction she experienced. The patient was sent to the emergency room to rule out phlebitis. The patient did not have phlebitis and was not hospitalized. The patient was treated with unspecified oral antibiotics for 10 days and symptoms improved. At the time of this report. the paint was recovering. The physician expressed concern for lot 65032/1039P and requested a lot check to be performed on the lot. The physician felt that cellulitis type reaction, pain, swelling, redness and fever were disabling and were other medical events. Additional information has been requested.
This spontaneous report as received from a pharmacist via a field representative refers to a patient of unknown age and gender. Relevant medical history and concomitant medication were not provided. In August 2012 the patient was vaccinated with ZOSTAVAX, subcutaneous. Lot number, dose and frequency were not provided. In April 2013, reported as 8 months after receiving ZOSTAVAX, the patient experienced post herpetic neuralgia. The outcome of post herpetic neuralgia was unknown. The reporter causality was unknown. Additional information has been requested.
Information (and additional information on 23-OCT-2007) has been received from a physician concerning her 21 year old daughter with a penicillin allergy who in January 2007, was vaccinated with a first dose of Gardasil. Concomitant therapy included Levora. In April 2007, the patient was vaccinated with a second dose of Gardasil. The patient was vaccinated in the morning and by the evening had developed a headache. The patient sought unspecified medical attention. The headache lasted 4 hours and was treated with TYLENOL. The vaccination was not administered at the physician's office. The patient picked up the vaccine at the pharmacy, and her mother, who was a physician, administered the vaccine at home. The patient did not develop a headache afte rthe first injection.  Additional information has been requested.
Resident, , initially started on the 11th with mental status changes.  She was unable to follow directions, pocketing food, all new for her.  She was sent toHospital ( and she was sent back with orders to monitor and increase fluid intakes.  On 1/13/2021 was found seizing and was again transferred to hospital where she was admitted with a seizure diagnosis which is a new diagnosis for her.
given an extra dose of MENACTRA (with no reported adverse event); Initial information received on 21-Jun-2022 regarding an unsolicited valid  non-serious case received from a other health professional.  This case involves a 17 years old female patient who was given an extra dose of menactra (with no reported adverse event) while receiving vaccine MENINGOCOCCAL A-C-Y-W135 (D CONJ) VACCINE [MENACTRA].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On 21-Jun-2022, the patient received a 0.5ml of dose of suspect MENINGOCOCCAL A-C-Y-W135 (D CONJ) VACCINE (formulation, strength: unknown) lot U7268AA, expiration date: 22-Apr-2023, via intramuscular route in the right arm as Immunisation. The patient used the product for the first time.  On 21-JUN-2022 the patient was given an extra dose of menactra (with no reported adverse event) (extra dose administered) same day following the administration of MENINGOCOCCAL A-C-Y-W135 (D CONJ) VACCINE.  Action taken was not applicable.  It was not reported if the patient received a corrective treatment for the event (given an extra dose of MENACTRA (with no reported adverse event)).  At time of reporting, the outcome was Unknown for the event.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
This spontaneous report as received from an unspecified person who found a study refers to an unspecified number of female patients of unknown age. On an unknown date, the patients were vaccinated with a dose of GARDASIL (dose, frequency, lot# and expiration date were not reported) for prophylaxis. On an unknown date, the patients experienced premature ovarian failure. The outcome of the event was not reported. The relatedness between vaccination with GARDASIL and the event was not reported. This is one of several reports from the same source. Additional information is not expected.; Sender's Comments: GB-009507513-1604GBR014439: US-009507513-1702USA006689: IE-009507513-1508IRL006083: GB-009507513-1702BGR004046:
Caller mentioned that her sister had developed a hard, sensitive pink and painful feeling on the injection site; injection site area is hard, pink and painful; injection site area is hard, pink and painful; injection site area is hard, pink and painful; This is a spontaneous report from a contactable consumer. This consumer female (patient's sister) reported for her 42-year-old female consumer (patient) who received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; Solution for injection; Lot number: unknown) via an unspecified route of administration on 09May2021 (at 42-year-old) as dose 2, single for COVID-19 immunization. The patient's medical history and concomitant medications were not reported. She also mentioned that when her sister previously received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; Solution for injection; Lot number: unknown) via an unspecified route of administration on an unknown date as dose 1, single for COVID-19 immunization AND experienced minimum pain. Her sister has been putting cold compress to ease the pain as well. On an unknown date caller mentioned that her sister had developed a hard, sensitive pink and painful feeling on the injection site. Caller had an understanding that people may have varying reaction to the vaccine and she also said that she had solicited some information from their friends and some of their friends who got either the Moderna or Pfizer COVID19 vaccine had experienced these side effects for at least 7 days. In line with this, caller wanted to know as to how long these side effects normally last. So that they may know as to when they might need to consult a physician. She also mentioned that she got her 1st dose and had experienced minimal pain. She was wondering if she might experience the same side effect as her sister's for her 2nd dose scheduled on 01Jun2021. The event outcome was unknown.  Follow-up (12May2021): This is a follow-up spontaneous report from a contactable consumer. This consumer female (patient's sister) reported that:  Reporter declined to submit a report about patient. Reporter states that there is no problem, and she does not have anything to report. Reporter states these are pretty common side effects. Reporter thought calling the manufacture would be simple, and she could have her question answered, but this is not simple. Reporter thinks that this was pain.  No follow-up attempts were needed; information about lot/batch number could not be obtained.
Splotchy, itchy rash on left upper leg near MMRV injection site but not at same area. Gave Benadryl and monitored for 30 minutes. Rash and itching resolved.
The child was participating in a post-marketing evaluation of the safety of influenza virus vaccine live, intranasal (Flumist) in healthy children and healthy adults 5 through 49 years of age. A report was received a Bell's Palsy coincident to FluMist. A ten year old male received FluMist on 18Nov05 and was diagnosed with Bell's Palsy coincident to FluMist. A ten year old male received FluMist on 18Nov05 and was diagnosed with Bell's Palsy on 20Nov05. On 16Nov05, the child was seen in the ER for a headache at the left occiput (pain radiating to the left jaw, tingling on left side of face, runny nose, and nasal congestion. At that time, the child denied numbness or ear pain, but did mention being hit in the head with a dodge ball two weeks prior to that ER visit. On 20Nov05, the child was unable to fully close the left eyelid, could not move the left side of the mouth or face, had decreased sensation in the left side of the face and was diagnosed with mild Bell's Palsy. The child was able to raise his eyebrows and the rest of the neurological examination was within normal limits. The child was treated with prednisolone 30mg twice a day for ten days (to be weaned as per protocol). And acyclovir 400mg by mouth five times per day for ten days. A recommendation was made to check the child in one month; however, the recommendation was not adhered to and no visits were on record since 20Nov05. The outcome of the event was not reported. The reporter assessed the event as possibly related to Flumist. Follow-up: 08 Dec 06 per the investigation, since 30 Jun 06, there was no mention made of BELL's Palsy Tx. Reminder: This case ongoing from FM025 which is a study.
Pt recieved shots and left room. Went out to waiting room to wait for mother to check out, patient went down to her knees and then passed out and hit head on the floor.
Vaccine was injected as an intramuscular injection. Public health notified us with our error. Vaccine does not need to be reinjected.
FOCAL MOTOR SEIZURE 4/26/2023 ATRIAL FIBRILLATION, UNSPECIFIED FOCAL MOTOR SEIZURE 4/26/2023 ATRIAL FIBRILLATION, UNSPECIFIED
Had lateral thoracic exanthema where vax administered. By 5/30/300 rash spreading puritic diffuse papular inticanial erythematous, rash , trunk. By 6/1 rash progressed to leg and facial area. Temp. up to 103.5 5/31 pm & 6/1 am.
Within 2 hours muscle started to become sore. By 8 hours post vaccination the muscle was severely painful as well as surrounding areas including left shoulder and left side of the neck. Pain was debilitating, treated with ibuprofen, tylenol and alternating heat and ice. Pain level finally started to decrease about 34 hours post vaccination and by day 4 post vaccination pain was completely resolved.
Sore throat; Stuffy nose; Night mares; Woke up every half an hour at night; Not focused; Nauseous; Soreness at the injection site; Fatigue; Patient whole body went completely numb 2 minutes after vaccination; Diarrhea; Loss of taste; Loss of smell; This spontaneous case was reported by a consumer and describes the occurrence of HYPOAESTHESIA (Patient whole body went completely numb 2 minutes after vaccination), DIARRHOEA (Diarrhea), AGEUSIA (Loss of taste), ANOSMIA (Loss of smell) and OROPHARYNGEAL PAIN (Sore throat) in a 41-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025B21A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 03-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Apr-2021, the patient experienced HYPOAESTHESIA (Patient whole body went completely numb 2 minutes after vaccination), DIARRHOEA (Diarrhea), AGEUSIA (Loss of taste), ANOSMIA (Loss of smell), NAUSEA (Nauseous), VACCINATION SITE PAIN (Soreness at the injection site) and FATIGUE (Fatigue). On 04-Apr-2021, the patient experienced OROPHARYNGEAL PAIN (Sore throat), NASAL CONGESTION (Stuffy nose), NIGHTMARE (Night mares), SLEEP DISORDER (Woke up every half an hour at night) and FEELING ABNORMAL (Not focused). The patient was treated with PARACETAMOL (TYNELOL) at an unspecified dose and frequency. At the time of the report, HYPOAESTHESIA (Patient whole body went completely numb 2 minutes after vaccination), DIARRHOEA (Diarrhea), AGEUSIA (Loss of taste), ANOSMIA (Loss of smell), OROPHARYNGEAL PAIN (Sore throat), NASAL CONGESTION (Stuffy nose), NIGHTMARE (Night mares), SLEEP DISORDER (Woke up every half an hour at night), FEELING ABNORMAL (Not focused), NAUSEA (Nauseous), VACCINATION SITE PAIN (Soreness at the injection site) and FATIGUE (Fatigue) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant and treatment medicine has been reported by reporter.  Patient stated that she was on periods when received the vaccine.
Rash that blistered; Cluster of boils under armpit; This spontaneous case was reported by a consumer and describes the occurrence of RASH VESICULAR (Rash that blistered) and FURUNCLE (Cluster of boils under armpit) in an 81-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 013M20A and 013L20A) for COVID-19 vaccination.     The patient's past medical history included Hip surgery. Concomitant products included LIDOCAINE for an unknown indication.   On 12-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 08-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced RASH VESICULAR (Rash that blistered) and FURUNCLE (Cluster of boils under armpit). At the time of the report, RASH VESICULAR (Rash that blistered) and FURUNCLE (Cluster of boils under armpit) outcome was unknown.            After the second dose, the patient used a lidocaine patch (date and reason not specified) where it developed a rash that blistered and she was "hospitalized in the emergency room".  Treatment included prednisone.  The patient developed a cluster of boils under her armpit after being prescribed prednisone.   This case was linked to US-MODERNATX, INC.-MOD-2021-081409 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-081409:First Dose
Tunnel vision, restlessness, unable to control extremities, vomiting, confusion, persistent lethargy, loss of strength over last 8 months, facial spasms. And I still was infected with covid 19
weakness in legs; Difficulty to walk; This spontaneous case was reported by a consumer and describes the occurrence of MUSCULAR WEAKNESS (weakness in legs) and GAIT DISTURBANCE (Difficulty to walk) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 14-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced MUSCULAR WEAKNESS (weakness in legs) and GAIT DISTURBANCE (Difficulty to walk). At the time of the report, MUSCULAR WEAKNESS (weakness in legs) and GAIT DISTURBANCE (Difficulty to walk) outcome was unknown.            No concomitant medications reported by investigator o No treatment medications provided by the reporter.
popped blood vessels in eyes from intensity of vomiting; vomiting for several days; Patient is pregnant; This is a spontaneous report from a contactable consumer. A 45-year-old pregnant female patient received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration, administered in left arm on 09Sep2021 (Batch/Lot number was not reported) (at the age of 45 years old) as single dose for Covid-19 immunisation. The patient medical history was not reported. It was unknown if patient had other vaccine in four weeks, and unknown if patient had other medications in two weeks. The first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE) was administered via intramuscular in Aug2021 for Covid-19 immunisation. The patient's concomitant medications were not reported. The patient was pregnant when she received the vaccine on 09Sep2021, she was 25 weeks pregnant. The patient reported that on 10Sep2021, she was vomiting for several days and popped blood vessels in eyes from intensity of vomiting. It was unknown if she received any treatment. Outcome of the events was recovering.    The lot number for the vaccine, BNT162B2, was not provided and will be requested during follow-up.
Tinnitus; This is a spontaneous report from a contactable consumer reported for herself. A 54-years-old female patient received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number=PFZ39), via an unspecified route of administration in left arm on 14Jan2021 19:00 at first single dose for covid-19 immunisation. Medical history included obesity, depression, hypothyroidism.  Other medications the patient received within 2 weeks of vaccination included: levothyroxine sodium (SYNTHROID), bupropion hydrochloride (WELLBUTRIN) and vitamin supplements. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient previously took demerol and experienced drug hypersensitivity. The patient experienced tinnitus on 14Jan2021 20:00 with outcome of not recovered. Since about an hour after receiving the vaccine, the patient's ears had been ringing. She had never experienced this before. It's noticeable but did not interfere with daily activities. Event was considered as non-serious. No treatment was received for the adverse event. Prior to vaccination, was the patient was not diagnosed with COVID-19. Since the vaccination, the patient has not been tested for COVID-19.
*Quarter size red mark on left leg. It is firm to the touch. *Treat with Topical Benedryl & oral Ibu. Told to schedule appt. if red area spreads or if a fever develops.
p/vax exp light diarrhea, sneezing x 7 days, cough;pt also resp rash starting on arms of inj site, trunks & extremities;rash described as hard & itchy;lungs & redness @ inj site 2 1/2 inches wide;
low-grade fever (100.8), pain at injection site, body aches (especially head and back), chills, exhaustion, weakness, nausea  These symptoms lasted for about 24 hours, although fatigue, weakness and pain continued to a lesser extent the following day, without fever.
Rash on bilateral arms and bilateral inner thighs that began on 1/7/2021. Rash is red, itchy and painful. Was prescribed Triamcinolone cream to apply to areas 2 times a day with no relief. Have tried hydrocortisone cream with no relief as well as OTC benadryl with no relief.  Continue to have painful rash today on 1/16/2021.
Information has been received on 25-APR-2017 from a medical assistant regarding an unspecified number of patients of unknown ages and gender. The patients' concurrent conditions, medical history and concomitant medications were not reported. From 13-APR-2017 through 25-APR-2017, an unspecified number of patients were vaccinated with doses of PROQUAD lot # M043306, expiration 24-APR-2018 and lot # M042502, expiration 17-APR-2018 subcutaneous for prophylaxis which were improperly stored. Other suspect therapy included sterile diluent lot # M034763 expiration 22-APR-2019. The vaccines were stored between 6 degrees Fahrenheit and 14 degrees Fahrenheit for 4 hours and 14 minutes. There was no previous temperature excursion. The call was not made due to a data logger. The medical assistant confirmed that the sterile diluent used to reconstitute the PROQUAD was not improperly stored. No adverse effects were reported. No further information was reported. Follow up information was received from the medical assistant on 17-MAY-2017, referring to an 11 month old male patient. The patient administered the vaccine on 21-APR-2017. The medical assistant reported that they did not exactly know what caused the temperature excursion in April 2017, but they were thinking the door to the refrigerator might have been left slightly open. There had been no temperature excursions since that time. All telephone attempts to obtain follow-up information on 17-MAY-2017 had been unsuccessful. This is one of several reports received from the same reporter. Additional information has been requested. Sender's Comments: US-009507513-1704USA013406: US-009507513-1705USA014055: US-009507513-1705USA014056: US-009507513-1705USA014057: US-009507513-1705USA014058: US-009507513-1705USA014059: US-009507513-1705USA014060: US-009507513-1705USA014061: US-009507513-1705USA014063: US-009507513-1705USA014064: US-009507513-1705USA014065: US-009507513-1705USA014066: US-009507513-1705USA014067: US-009507513-1705USA014068.
pt recv vax 27AUG96 & SEP96 pt was exposed to contagious sibling;1wk later 23SEP96 pt devel a rash w/about 30 lesions on chest, back, scalp, face & some on the arms;
This 93 year old white female hospice patient received the Covid shot on 1/20/2021 and went to the ED on 3/12 for COPD exacerbation, shortness of breath and extremity weakness.  She returned to the ED on 3/13/21 and was admitted for generalized weakness and dehydration.  The patient subsequently died on 4/13/21. Please refer to the other details submitted within this report and contact the person who submitted this report via email for additional follow up details and investigation.
Severe chills and shaking, fever ranging from 99-101.7 F, muscle aches, joint aches, headache lasting from 1 am - 11 pm 3/6 (day after injection). Acetaminophen every 8 hours, beginning at 3 am; ibuprofen every 8 hours beginning at 4 pm.  Felt some general weakness on Sunday.
Cellulitis on right thigh, rash of lower right extremity. swelling to lower right extremity.
Began suffering chest pain at home at 12:30 AM on Friday, April 30, 2021 and drove to hospital. Upon arrival-suffered heart attack and was rushed to Hospital by ambulance where I was given a stent in my right coronary artery which saved my life. Full blockage in that artery with Blood Pressure of 50/30 at time of my MI.
Systemic: Chills-Severe, Systemic: Fainting / Unresponsive-Severe, Systemic: Hypotension-Medium, Systemic: Seizure-Severe
Pt was admitted to the hospital from ED with A-fib on 4/8/2021 after receiving first dose of vaccine on 3/30/21. Per guidelines, all hospitalizations are reported.
Sunday evening around 9pm I had the chills and I got a severe headache. I shook for 3 hours. I had a fever of 99.7. I was cold all night. I started shivering again the next morning for 2 hours. around 1:30 in the afternoon I was a little better. Sunday night I had fever again and was shaking and very cold. I had a bad headache the whole time. Monday I seemed to be ok, but I did wake up itching. I have a red splotchy rash all over my body. my legs are bright solid red and I itch all over!
He got the vaccine, was not able to breath real good and didn't think about it.  It got to the point within 2 weeks that he was not able to get up from the chair due to the shortness of breath.  By 4/1/21 he was not able to breath very well, but continued to stay home.  Then by 4/12/21 he was not able to breath well at all and his wife took him to the ER.  In the hospital they did x-rays and found out that his lungs are full of blood clots and both legs have blood clots in them.  He was admitted and gave him Heparin drip for the 2 days to get the blood clots dissolved and was also on oxygen for 2 days.  He was discharged home yesterday with Xarelto, and was told that he would be on that for the rest of his life, and is on oxygen for sleep and when he's up and around, but if he's resting and feels he's breathing okay he can remove it.   They informed him that it would take approximately 2 months for all the blood clots to dissipate, and that he was full of blood clots, and had both legs and both lungs which are quite full.